COVID-19 vaccine developer CureVac shares more than triple after U.S. debut

Aug 14 (Reuters) – Shares of German biotechnology firm CureVac BV soared as much as 222% after their Nasdaq debut on Friday, in the first stock market opening of a company developing a potential vaccine to combat the novel coronavirus.


You can find the complete original obituary on this website.

Obituariues recently published

Leave a Reply

Your email address will not be published.

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.